GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arcturus Therapeutics Holdings Inc (NAS:ARCT) » Definitions » Book Value per Share

Arcturus Therapeutics Holdings (Arcturus Therapeutics Holdings) Book Value per Share : $10.38 (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Arcturus Therapeutics Holdings Book Value per Share?

Arcturus Therapeutics Holdings's book value per share for the quarter that ended in Dec. 2023 was $10.38.

During the past 12 months, Arcturus Therapeutics Holdings's average Book Value Per Share Growth Rate was 2.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -11.80% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 54.80% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 0.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Arcturus Therapeutics Holdings was 154.40% per year. The lowest was -74.80% per year. And the median was 62.00% per year.

Arcturus Therapeutics Holdings's current price is $25.57. Its book value per share for the quarter that ended in Dec. 2023 was $10.38. Hence, today's PB Ratio of Arcturus Therapeutics Holdings is 2.46.

During the past 13 years, the highest P/B Ratio of Arcturus Therapeutics Holdings was 52.03. The lowest was 0.67. And the median was 3.01.


Arcturus Therapeutics Holdings Book Value per Share Historical Data

The historical data trend for Arcturus Therapeutics Holdings's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arcturus Therapeutics Holdings Book Value per Share Chart

Arcturus Therapeutics Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.70 15.14 8.65 10.18 10.38

Arcturus Therapeutics Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.18 12.40 10.73 10.48 10.38

Competitive Comparison of Arcturus Therapeutics Holdings's Book Value per Share

For the Biotechnology subindustry, Arcturus Therapeutics Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arcturus Therapeutics Holdings's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arcturus Therapeutics Holdings's PB Ratio distribution charts can be found below:

* The bar in red indicates where Arcturus Therapeutics Holdings's PB Ratio falls into.



Arcturus Therapeutics Holdings Book Value per Share Calculation

Arcturus Therapeutics Holdings's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(278.5-0.0)/26.8
=10.38

Arcturus Therapeutics Holdings's Book Value Per Share for the quarter that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(278.5-0.0)/26.8
=10.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Arcturus Therapeutics Holdings  (NAS:ARCT) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Arcturus Therapeutics Holdings Book Value per Share Related Terms

Thank you for viewing the detailed overview of Arcturus Therapeutics Holdings's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Arcturus Therapeutics Holdings (Arcturus Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
10628 Science Center Drive, Suite 250, San Diego, CA, USA, 92121
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of the company includes LUNAR-OTC, LUNAR-CF, and LUNAR-COV19.
Executives
Pad Chivukula officer: Chief Scientific Officer & COO 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Keith C Kummerfeld officer: See Remarks 10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121
Magda Marquet director ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
John Markels director C/O SANGAMO THERAPEUTICS, INC., POINT RICHMOND TECH CTR, 501 CANAL BLVD., RICHMOND CA 94804
Joseph E Payne director, 10 percent owner, officer: President and CEO 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Jing L. Marantz director C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Ultragenyx Pharmaceutical Inc. director, 10 percent owner 60 LEVERONI COURT, NOVATO CA 94949
Lance Kurata officer: Chief Legal Officer 10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121
Andy Sassine officer: Chief Financial Officer 82 DEVONSHIRE STREET, BOSTON MA 02109
Steven George Hughes officer: Chief Development Officer 6275 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
James F Barlow director 2525 DUPONT DR, IRVINE CA 92612
Edward W Holmes director C/O TULARIK INC, TWO CORP DRIVE SOUTH, SAN FRANCISCO CA 8608257208
Peter C Farrell director RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Karah Herdman Parschauer director 60 LEVERONI COURT, NOVATO CA 94949